Oneal comprehensive cancer center
The study provides doctors and researchers with a more accurate way to identify patients at the highest risk of early relapse and may help guide earlier use of newer immunotherapies.
Without intervention, physician Edwin Villarreal’s prognosis was 100 percent mortality; but he is alive and well after receiving treatment for an often-fatal condition, HLH.
The projects represent an investment in neighborhood revitalization and community well-being.
UAB researchers report Phase 1 trial results showing a novel immunotherapy was well-tolerated and doubled the progression-free survival time in glioblastoma patients, offering new optimism for improving survival and quality of life.
Few centers in the Southeast offer this procedure, and the national allocation system does not typically prioritize patients with colorectal metastases — meaning extended waits on the transplantation list for these patient populations.
The transplant offers a new treatment option for the more than 18,500 Americans yearly who are diagnosed with blood cancers and need a bone marrow transplant.
A $2 million investment will allow patients to enjoy greater scheduling flexibility, fewer treatment delays and better support for complex diagnoses.
The AMPLIFY Diet intervention helps older survivors of obesity-related cancers achieve meaningful weight loss and improvements in key health outcomes without in‑person visits, coaching calls or live counseling.
A UAB professor leads a new discovery that could change how an aggressive thyroid cancer with limited treatments is approached and treated.
Participate in a health screening, learn about community resources, and engage with health care professionals at this year’s Regional Wellness Day.
UAB researchers are advancing cancer prevention and treatment through lifestyle-based survivorship care, adaptive molecular therapies and precision biomedical engineering.
Cardiovascular disease is the second leading cause of death among cancer survivors, second only to cancer itself
The MajesTEC-3 clinical trial shows that using a new two-drug immunotherapy regimen can lead to long-lasting remission for patients with multiple myeloma. Over 83 percent of patients enrolled in the trial are alive and progression-free three years after therapy.
Heidi Neas was diagnosed with cancer at 16 weeks pregnant, became cancer-free at 22 weeks and delivered a healthy baby boy.
UAB experts, medical students and undergraduate students are dedicated to raising awareness of cervical cancer and promoting information on prevention, diagnosis and treatment.
The proceeds from the gala will be put toward O’Neal Invests — a fund focused on high-priority research efforts.
Technology and treatment planning have made shorter-course radiation a safe, effective and patient-centered option for breast cancer care.
A UAB urologist has been selected as a recipient of the highly competitive 2025 National Cancer Institute Early Career Cancer Clinical Investigator Award.
At just 43 years old, Latrivia Carter was diagnosed with stage 2 triple-negative breast cancer.
UAB physicians say this type of cancer treatment is often associated with higher cure rates, longer life spans, better outcomes and fewer side effects.